Two Novel Semisynthetic Lipoglycopeptides Active against Staphylococcus aureus Biofilms and Cells in Late Stationary Growth Phase

0550795 - MBÚ 2022 RIV CH eng J - Článek v odborném periodiku
Vimberg, Vladimír - Zieglerová, Leona - Mazumdar, Aninda - Szucs, Z. - Borbas, A. - Herczegh, P. - Balíková Novotná, Gabriela
Two Novel Semisynthetic Lipoglycopeptides Active against Staphylococcus aureus Biofilms and Cells in Late Stationary Growth Phase.
Pharmaceuticals. Roč. 14, č. 11 (2021), č. článku 1182. E-ISSN 1424-8247
Grant CEP: GA MZd(CZ) NV15-28807A; GA MŠMT(CZ) ED1.1.00/02.0109
Institucionální podpora: RVO:61388971
Klíčová slova: antibiotic resistance * glycopeptide antibiotics * Staphylococcus aureus * teicoplanin pseudoaglycon
Obor OECD: Microbiology
Impakt faktor: 5.215, rok: 2021
Způsob publikování: Open access
https://www.mdpi.com/1424-8247/14/11/1182

The increase in antibiotic resistance among Gram-positive bacteria underscores the urgent need to develop new antibiotics. New antibiotics should target actively growing susceptible bacteria that are resistant to clinically accepted antibiotics including bacteria that are not growing or are protected in a biofilm environment. In this paper, we compare the in vitro activities of two new semisynthetic glycopeptide antibiotics, MA79 and ERJ390, with two clinically used glycopeptide antibiotics-vancomycin and teicoplanin. The new antibiotics effectively killed not only exponentially growing cells of Staphylococcus aureus, but also cells in the stationary growth phase and biofilm.
Trvalý link: http://hdl.handle.net/11104/0326103